drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01254 | DB06288 | 1,213 | 607 | [
"DDInter484",
"DDInter77"
] | Dasatinib | Amisulpride | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Major | 2 | [
[
[
1213,
25,
607
]
],
[
[
1213,
7,
2475
],
[
2475,
46,
607
]
],
[
[
1213,
21,
29232
],
[
29232,
60,
607
]
],
[
[
1213,
62,
112
],
[
112,
... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Dasatinib",
"{u} (Compound) upregulates {v} (Gene)",
"RGS2"
],
[
"RGS2",
"{u} (Gene) is upregulated by {v} (Compound)",
"... | Dasatinib (Compound) upregulates RGS2 (Gene) and RGS2 (Gene) is upregulated by Amisulpride (Compound)
Dasatinib (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Amisulpride (Compound)
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole ... |
DB00001 | DB08918 | 1,578 | 41 | [
"DDInter1037",
"DDInter1059"
] | Lepirudin | Levomilnacipran | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Moderate | 1 | [
[
[
1578,
24,
41
]
],
[
[
1578,
24,
901
],
[
901,
40,
41
]
],
[
[
1578,
25,
498
],
[
498,
63,
41
]
],
[
[
1578,
25,
330
],
[
330,
24... | [
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
... | Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Lepirudin may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbate di... |
DB00850 | DB11057 | 1,630 | 720 | [
"DDInter1432",
"DDInter1223"
] | Perphenazine | Mineral oil | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1630,
24,
720
]
],
[
[
1630,
24,
927
],
[
927,
63,
720
]
],
[
[
1630,
24,
1151
],
[
1151,
24,
720
]
],
[
[
1630,
25,
1069
],
[
1069,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and ... |
DB00031 | DB11703 | 20 | 405 | [
"DDInter1764",
"DDInter9"
] | Tenecteplase | Acalabrutinib | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
20,
25,
405
]
],
[
[
20,
24,
383
],
[
383,
24,
405
]
],
[
[
20,
24,
738
],
[
738,
63,
405
]
],
[
[
20,
24,
804
],
[
804,
25,
... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken... |
DB00595 | DB01144 | 1,545 | 1,326 | [
"DDInter1374",
"DDInter540"
] | Oxytetracycline | Diclofenamide | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Minor | 0 | [
[
[
1545,
23,
1326
]
],
[
[
1545,
23,
504
],
[
504,
1,
1326
]
],
[
[
1545,
23,
359
],
[
359,
40,
1326
]
],
[
[
1545,
40,
1620
],
[
1620,
... | [
[
[
"Oxytetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diclofenamide"
]
],
[
[
"Oxytetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazid... | Oxytetracycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound)
Oxytetracycline may cause a minor interaction that can limit clinical effects when taken with Chlorothiazide and Chlorothiazide (Compoun... |
DB10989 | DB12498 | 496 | 76 | [
"DDInter858",
"DDInter1238"
] | Hepatitis A Vaccine | Mogamulizumab | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become canc... | Moderate | 1 | [
[
[
496,
24,
76
]
],
[
[
496,
63,
1531
],
[
1531,
24,
76
]
],
[
[
496,
24,
738
],
[
738,
24,
76
]
],
[
[
496,
24,
676
],
[
676,
64,
... | [
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canaki... | Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00372 | DB00657 | 999 | 1,360 | [
"DDInter1793",
"DDInter1130"
] | Thiethylperazine | Mecamylamine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. | Moderate | 1 | [
[
[
999,
24,
1360
]
],
[
[
999,
24,
1344
],
[
1344,
63,
1360
]
],
[
[
999,
24,
1466
],
[
1466,
24,
1360
]
],
[
[
999,
24,
1344
],
[
1344,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mecamylamine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Mecamylamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with P... |
DB04868 | DB05812 | 478 | 1,374 | [
"DDInter1293",
"DDInter8"
] | Nilotinib | Abiraterone | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Major | 2 | [
[
[
478,
25,
1374
]
],
[
[
478,
63,
1561
],
[
1561,
1,
1374
]
],
[
[
478,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
478,
21,
29113
],
[
29113... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
[
"Testoster... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Abiraterone (Compound)
Nilotinib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Nilotinib (Compound) causes Hypokalaemia (Side Effect) and Hyp... |
DB00963 | DB11921 | 1,263 | 1,019 | [
"DDInter241",
"DDInter492"
] | Bromfenac | Deflazacort | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
1263,
24,
1019
]
],
[
[
1263,
24,
959
],
[
959,
24,
1019
]
],
[
[
1263,
64,
629
],
[
629,
24,
1019
]
],
[
[
1263,
1,
831
],
[
831,
... | [
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Bromfenac may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a mod... |
DB11581 | DB11601 | 1,456 | 1,270 | [
"DDInter1926",
"DDInter1889"
] | Venetoclax | Tuberculin purified protein derivative | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lym... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1456,
24,
1270
]
],
[
[
1456,
63,
1531
],
[
1531,
24,
1270
]
],
[
[
1456,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
1456,
24,
119
],
[
119... | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Venetoclax may lead to a major life threatening interaction when taken with Cladri... |
DB00938 | DB06603 | 455 | 39 | [
"DDInter1635",
"DDInter1387"
] | Salmeterol | Panobinostat | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
455,
24,
39
]
],
[
[
455,
63,
867
],
[
867,
24,
39
]
],
[
[
455,
64,
1091
],
[
1091,
24,
39
]
],
[
[
455,
24,
688
],
[
688,
24,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Salmeterol may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may caus... |
DB00065 | DB00363 | 581 | 695 | [
"DDInter923",
"DDInter419"
] | Infliximab | Clozapine | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Major | 2 | [
[
[
581,
25,
695
]
],
[
[
581,
24,
902
],
[
902,
40,
695
]
],
[
[
581,
24,
1565
],
[
1565,
1,
695
]
],
[
[
581,
24,
112
],
[
112,
62... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
"Clobazam",
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Clozapine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam and Clonazepam (Compound) resembles Clozapine (Compound)
Inflix... |
DB01218 | DB11978 | 1,493 | 124 | [
"DDInter852",
"DDInter822"
] | Halofantrine | Glasdegib | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Major | 2 | [
[
[
1493,
25,
124
]
],
[
[
1493,
62,
1247
],
[
1247,
23,
124
]
],
[
[
1493,
24,
327
],
[
327,
24,
124
]
],
[
[
1493,
25,
1079
],
[
1079,
... | [
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Halofantrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sul... | Halofantrine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Abametapir... |
DB00196 | DB01044 | 600 | 246 | [
"DDInter743",
"DDInter809"
] | Fluconazole | Gatifloxacin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Major | 2 | [
[
[
600,
25,
246
]
],
[
[
600,
24,
739
],
[
739,
1,
246
]
],
[
[
600,
25,
1176
],
[
1176,
1,
246
]
],
[
[
600,
25,
945
],
[
945,
40,... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lome... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Fluconazole may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (Compound)
F... |
DB00631 | DB11793 | 372 | 738 | [
"DDInter405",
"DDInter1297"
] | Clofarabine | Niraparib | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
372,
24,
738
]
],
[
[
372,
63,
663
],
[
663,
24,
738
]
],
[
[
372,
24,
496
],
[
496,
24,
738
]
],
[
[
372,
24,
1619
],
[
1619,
6... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vacc... |
DB04855 | DB04951 | 540 | 187 | [
"DDInter602",
"DDInter1477"
] | Dronedarone | Pirfenidone | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Moderate | 1 | [
[
[
540,
24,
187
]
],
[
[
540,
25,
1670
],
[
1670,
63,
187
]
],
[
[
540,
24,
1017
],
[
1017,
63,
187
]
],
[
[
540,
63,
1419
],
[
1419,
... | [
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
]
],
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglus... | Dronedarone may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cau... |
DB05578 | DB11071 | 330 | 1,004 | [
"DDInter1566",
"DDInter1449"
] | Ramucirumab | Phenyl salicylate | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in ). Phenyl salicylate ma... | Major | 2 | [
[
[
330,
25,
1004
]
],
[
[
330,
64,
500
],
[
500,
24,
1004
]
],
[
[
330,
25,
498
],
[
498,
24,
1004
]
],
[
[
330,
25,
235
],
[
235,
... | [
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
... | Ramucirumab may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Ramucirumab may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate... |
DB11718 | DB13074 | 927 | 877 | [
"DDInter640",
"DDInter1110"
] | Encorafenib | Macimorelin | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
927,
25,
877
]
],
[
[
927,
62,
112
],
[
112,
23,
877
]
],
[
[
927,
24,
1320
],
[
1320,
24,
877
]
],
[
[
927,
64,
651
],
[
651,
2... | [
[
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Encorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Encorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Ela... |
DB00938 | DB01242 | 455 | 1,237 | [
"DDInter1635",
"DDInter410"
] | Salmeterol | Clomipramine | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
455,
24,
1237
]
],
[
[
455,
63,
684
],
[
684,
1,
1237
]
],
[
[
455,
24,
401
],
[
401,
24,
1237
]
],
[
[
455,
24,
9
],
[
9,
1,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction ... |
DB00681 | DB00999 | 1,287 | 504 | [
"DDInter85",
"DDInter883"
] | Amphotericin B | Hydrochlorothiazide | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Moderate | 1 | [
[
[
1287,
24,
504
]
],
[
[
1287,
24,
1326
],
[
1326,
40,
504
]
],
[
[
1287,
24,
178
],
[
178,
1,
504
]
],
[
[
1287,
63,
323
],
[
323,
... | [
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenam... | Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide (Compound) resembles Hydrochlorothiazide (Compound)
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resem... |
DB00086 | DB00584 | 1,167 | 610 | [
"DDInter1712",
"DDInter638"
] | Streptokinase | Enalapril | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Moderate | 1 | [
[
[
1167,
24,
610
]
],
[
[
1167,
24,
743
],
[
743,
1,
610
]
],
[
[
1167,
24,
954
],
[
954,
40,
610
]
],
[
[
1167,
24,
714
],
[
714,
... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
],
... | Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril (Compound) resembles Enalapril (Compound)
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Enalapril (Compound... |
DB00444 | DB01098 | 63 | 14 | [
"DDInter1765",
"DDInter1622"
] | Teniposide | Rosuvastatin | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Moderate | 1 | [
[
[
63,
24,
14
]
],
[
[
63,
24,
671
],
[
671,
24,
14
]
],
[
[
63,
6,
8374
],
[
8374,
45,
14
]
],
[
[
63,
7,
4634
],
[
4634,
46,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Teniposide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rosuvastatin (Compound)
Teniposide (... |
DB00531 | DB11627 | 450 | 1,367 | [
"DDInter456",
"DDInter860"
] | Cyclophosphamide | Hepatitis B Vaccine (Recombinant) | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
450,
24,
1367
]
],
[
[
450,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
450,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
450,
24,
259
],
[
259,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",... | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Cyclophosphamide may lead to a major life threatening interaction when taken with... |
DB00065 | DB00349 | 581 | 902 | [
"DDInter923",
"DDInter401"
] | Infliximab | Clobazam | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | Moderate | 1 | [
[
[
581,
24,
902
]
],
[
[
581,
24,
1382
],
[
1382,
1,
902
]
],
[
[
581,
25,
695
],
[
695,
1,
902
]
],
[
[
581,
25,
168
],
[
168,
23,... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
],
[
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam (Compound) resembles Clobazam (Compound)
Infliximab may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Clobazam (Compound)
Infliximab may lead to ... |
DB00719 | DB00754 | 1,219 | 157 | [
"DDInter149",
"DDInter696"
] | Azatadine | Ethotoin | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Moderate | 1 | [
[
[
1219,
24,
157
]
],
[
[
1219,
24,
759
],
[
759,
40,
157
]
],
[
[
1219,
24,
1264
],
[
1264,
63,
157
]
],
[
[
1219,
63,
128
],
[
128,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
"... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate ... |
DB00668 | DB06262 | 874 | 1,354 | [
"DDInter652",
"DDInter606"
] | Epinephrine | Droxidopa | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a def... | Moderate | 1 | [
[
[
874,
24,
1354
]
],
[
[
874,
40,
584
],
[
584,
40,
1354
]
],
[
[
874,
24,
1191
],
[
1191,
40,
1354
]
],
[
[
874,
24,
1148
],
[
1148,
... | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droxidopa"
]
],
[
[
"Epinephrine",
"{u} (Compound) resembles {v} (Compound)",
"Levonordefrin"
],
[
"Levonordefrin",
"{u} (Compound) r... | Epinephrine (Compound) resembles Levonordefrin (Compound) and Levonordefrin (Compound) resembles Droxidopa (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa (Compound) resembles Droxidopa (Compound)
Epinephrine may cause a moderate interaction t... |
DB00615 | DB11921 | 690 | 1,019 | [
"DDInter1589",
"DDInter492"
] | Rifabutin | Deflazacort | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
690,
25,
1019
]
],
[
[
690,
24,
959
],
[
959,
24,
1019
]
],
[
[
690,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
690,
25,
629
],
[
629,
... | [
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
... | Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib ... |
DB01132 | DB11799 | 1,130 | 627 | [
"DDInter1472",
"DDInter205"
] | Pioglitazone | Bictegravir | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Moderate | 1 | [
[
[
1130,
24,
627
]
],
[
[
1130,
24,
478
],
[
478,
24,
627
]
],
[
[
1130,
63,
1419
],
[
1419,
24,
627
]
],
[
[
1130,
62,
1051
],
[
1051,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imati... |
DB00059 | DB00624 | 1,560 | 1,561 | [
"DDInter1404",
"DDInter1776"
] | Pegaspargase | Testosterone (topical) | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Testosterone is an androstanoid having 17beta-hydroxy and 3-oxo groups, together with unsaturation at C-4-C-5.. It has a role as an androgen, a human metabolite, a Daphnia magna metabolite and a mouse metabolite. It is a 17beta-hydroxy steroid, an androstanoid, a C19-steroid and a 3-oxo-Delta(4) steroid. | Moderate | 1 | [
[
[
1560,
24,
1561
]
],
[
[
1560,
24,
155
],
[
155,
1,
1561
]
],
[
[
1560,
24,
1026
],
[
1026,
40,
1561
]
],
[
[
1560,
24,
891
],
[
891,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxymesterone"
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Testosterone
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone and Fluoxymesterone (Compound) resembles Testosterone (Compound)
Pegaspargase may cause a moderate intera... |
DB00342 | DB01224 | 1,181 | 623 | [
"DDInter1770",
"DDInter1553"
] | Terfenadine | Quetiapine | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
1181,
24,
623
]
],
[
[
1181,
24,
827
],
[
827,
1,
623
]
],
[
[
1181,
25,
851
],
[
851,
1,
623
]
],
[
[
1181,
63,
867
],
[
867,
1... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
[
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Terfenadine may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone (Compound) resembles Quetiapine (Compound)
Terfenadine may... |
DB00264 | DB11130 | 88 | 407 | [
"DDInter1200",
"DDInter1344"
] | Metoprolol | Opium | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
88,
24,
407
]
],
[
[
88,
23,
1054
],
[
1054,
24,
407
]
],
[
[
88,
24,
976
],
[
976,
24,
407
]
],
[
[
88,
63,
352
],
[
352,
24,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Metoprolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Kaolin"
],
[
"Kaolin... | Metoprolol may cause a minor interaction that can limit clinical effects when taken with Kaolin and Kaolin may cause a moderate interaction that could exacerbate diseases when taken with Opium
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may caus... |
DB00835 | DB01148 | 100 | 1,128 | [
"DDInter245",
"DDInter738"
] | Brompheniramine | Flavoxate | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Moderate | 1 | [
[
[
100,
24,
1128
]
],
[
[
100,
6,
7992
],
[
7992,
45,
1128
]
],
[
[
100,
24,
537
],
[
537,
63,
1128
]
],
[
[
100,
63,
1123
],
[
1123,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flavoxate"
]
],
[
[
"Brompheniramine",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Comp... | Brompheniramine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Flavoxate (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Flavoxate
Brompheniramin... |
DB00330 | DB09122 | 238 | 1,613 | [
"DDInter689",
"DDInter1409"
] | Ethambutol | Peginterferon beta-1a | Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycob... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
238,
24,
1613
]
],
[
[
238,
63,
168
],
[
168,
24,
1613
]
],
[
[
238,
24,
267
],
[
267,
24,
1613
]
],
[
[
238,
24,
1480
],
[
1480,
... | [
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
... | Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone... |
DB00258 | DB01208 | 666 | 945 | [
"DDInter270",
"DDInter1705"
] | Calcium acetate | Sparfloxacin | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Moderate | 1 | [
[
[
666,
24,
945
]
],
[
[
666,
24,
739
],
[
739,
1,
945
]
],
[
[
666,
63,
1176
],
[
1176,
1,
945
]
],
[
[
666,
21,
29305
],
[
29305,
... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
... | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sp... |
DB00581 | DB00819 | 355 | 471 | [
"DDInter1018",
"DDInter15"
] | Lactulose | Acetazolamide | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Moderate | 1 | [
[
[
355,
24,
471
]
],
[
[
355,
24,
997
],
[
997,
40,
471
]
],
[
[
355,
21,
28709
],
[
28709,
60,
471
]
],
[
[
355,
23,
286
],
[
286,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
],
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide (Compound) resembles Acetazolamide (Compound)
Lactulose (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Acetazolamide (Compound)
Lactulose may ca... |
DB00491 | DB14731 | 127 | 1,518 | [
"DDInter1217",
"DDInter1741"
] | Miglitol | Tagraxofusp | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by t... | Moderate | 1 | [
[
[
127,
24,
1518
]
],
[
[
127,
63,
176
],
[
176,
24,
1518
]
],
[
[
127,
24,
1411
],
[
1411,
24,
1518
]
],
[
[
127,
63,
695
],
[
695,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide ... |
DB00047 | DB00877 | 176 | 629 | [
"DDInter932",
"DDInter1678"
] | Insulin glargine | Sirolimus | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
176,
24,
629
]
],
[
[
176,
24,
1438
],
[
1438,
24,
629
]
],
[
[
176,
24,
1476
],
[
1476,
63,
629
]
],
[
[
176,
25,
839
],
[
839,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib a... |
DB00497 | DB01612 | 828 | 1,637 | [
"DDInter1366",
"DDInter92"
] | Oxycodone | Amyl Nitrite | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
828,
24,
1637
]
],
[
[
828,
64,
475
],
[
475,
24,
1637
]
],
[
[
828,
24,
401
],
[
401,
24,
1637
]
],
[
[
828,
25,
593
],
[
593,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
... | Oxycodone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause ... |
DB01377 | DB06824 | 1,283 | 29 | [
"DDInter1119",
"DDInter1864"
] | Magnesium oxide | Triethylenetetramine | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved... | Moderate | 1 | [
[
[
1283,
24,
29
]
],
[
[
1283,
62,
954
],
[
954,
24,
29
]
],
[
[
1283,
24,
286
],
[
286,
63,
29
]
],
[
[
1283,
24,
1596
],
[
1596,
... | [
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triethylenetetramine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinapril... | Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Triethylenetetramine
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magne... |
DB09143 | DB09280 | 313 | 1,604 | [
"DDInter1701",
"DDInter1101"
] | Sonidegib | Lumacaftor | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
313,
25,
1604
]
],
[
[
313,
62,
379
],
[
379,
24,
1604
]
],
[
[
313,
63,
522
],
[
522,
24,
1604
]
],
[
[
313,
64,
307
],
[
307,
... | [
[
[
"Sonidegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Sonidegib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole",... | Sonidegib may cause a minor interaction that can limit clinical effects when taken with Rabeprazole and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlu... |
DB04844 | DB12332 | 843 | 1,619 | [
"DDInter1778",
"DDInter1626"
] | Tetrabenazine | Rucaparib | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
843,
24,
1619
]
],
[
[
843,
63,
222
],
[
222,
23,
1619
]
],
[
[
843,
62,
112
],
[
112,
23,
1619
]
],
[
[
843,
24,
1662
],
[
1662,
... | [
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Tetrabenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and ... |
DB00861 | DB01250 | 914 | 712 | [
"DDInter551",
"DDInter1334"
] | Diflunisal | Olsalazine | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inf... | Moderate | 1 | [
[
[
914,
24,
712
]
],
[
[
914,
40,
220
],
[
220,
40,
712
]
],
[
[
914,
63,
50
],
[
50,
40,
712
]
],
[
[
914,
40,
345
],
[
345,
1,
... | [
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
]
],
[
[
"Diflunisal",
"{u} (Compound) resembles {v} (Compound)",
"Mesalazine"
],
[
"Mesalazine",
"{u} (Compound) resemble... | Diflunisal (Compound) resembles Mesalazine (Compound) and Mesalazine (Compound) resembles Olsalazine (Compound)
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Olsalazine (Compound)
Diflunisal (Compound) resembles Salsalate ... |
DB00564 | DB08882 | 1,236 | 1,281 | [
"DDInter293",
"DDInter1070"
] | Carbamazepine | Linagliptin | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
1236,
24,
1281
]
],
[
[
1236,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
1236,
21,
29081
],
[
29081,
60,
1281
]
],
[
[
1236,
63,
251
],
[
25... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Carbamazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Carbamazepine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Carbamazepine (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Linagliptin (Compound)
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Betame... |
DB00408 | DB06704 | 1,408 | 247 | [
"DDInter1099",
"DDInter951"
] | Loxapine | Iobenguane (I-123) | An antipsychotic agent used in schizophrenia. [PubChem] | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
1408,
24,
247
]
],
[
[
1408,
6,
7390
],
[
7390,
45,
247
]
],
[
[
1408,
21,
28787
],
[
28787,
60,
247
]
],
[
[
1408,
24,
820
],
[
820,
... | [
[
[
"Loxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iobenguane"
]
],
[
[
"Loxapine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Loxapine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Loxapine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound)
Loxapine may... |
DB00261 | DB08875 | 702 | 1,618 | [
"DDInter93",
"DDInter262"
] | Anagrelide | Cabozantinib | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
702,
25,
1618
]
],
[
[
702,
23,
112
],
[
112,
23,
1618
]
],
[
[
702,
24,
723
],
[
723,
24,
1618
]
],
[
[
702,
24,
1032
],
[
1032,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Ap... |
DB00575 | DB00792 | 1,020 | 832 | [
"DDInter412",
"DDInter1878"
] | Clonidine | Tripelennamine | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
1020,
24,
832
]
],
[
[
1020,
24,
100
],
[
100,
63,
832
]
],
[
[
1020,
25,
1264
],
[
1264,
63,
832
]
],
[
[
1020,
24,
649
],
[
649,
... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
... | Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Clonidine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may ... |
DB00816 | DB11642 | 1,674 | 938 | [
"DDInter1346",
"DDInter1480"
] | Orciprenaline | Pitolisant | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
1674,
24,
938
]
],
[
[
1674,
63,
600
],
[
600,
24,
938
]
],
[
[
1674,
24,
1228
],
[
1228,
24,
938
]
],
[
[
1674,
24,
927
],
[
927,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib an... |
DB01244 | DB08870 | 762 | 850 | [
"DDInter192",
"DDInter228"
] | Bepridil | Brentuximab vedotin | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
762,
24,
850
]
],
[
[
762,
63,
1512
],
[
1512,
24,
850
]
],
[
[
762,
24,
159
],
[
159,
63,
850
]
],
[
[
762,
64,
918
],
[
918,
2... | [
[
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
... | Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib an... |
DB01193 | DB12267 | 819 | 1,476 | [
"DDInter12",
"DDInter233"
] | Acebutolol | Brigatinib | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
819,
24,
1476
]
],
[
[
819,
63,
176
],
[
176,
24,
1476
]
],
[
[
819,
23,
578
],
[
578,
24,
1476
]
],
[
[
819,
24,
1276
],
[
1276,
... | [
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
... | Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Acebutolol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor ... |
DB00427 | DB00981 | 1,233 | 1,528 | [
"DDInter1879",
"DDInter1463"
] | Triprolidine | Physostigmine (ophthalmic) | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. | Moderate | 1 | [
[
[
1233,
24,
1528
]
],
[
[
1233,
63,
508
],
[
508,
24,
1528
]
],
[
[
1233,
24,
87
],
[
87,
24,
1528
]
],
[
[
1233,
24,
1511
],
[
1511,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Tr... |
DB06448 | DB11986 | 171 | 484 | [
"DDInter1087",
"DDInter648"
] | Lonafarnib | Entrectinib | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
171,
25,
484
]
],
[
[
171,
63,
112
],
[
112,
23,
484
]
],
[
[
171,
24,
466
],
[
466,
62,
484
]
],
[
[
171,
25,
1135
],
[
1135,
2... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metron... | Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and... |
DB06688 | DB06810 | 1,430 | 397 | [
"DDInter1677",
"DDInter1484"
] | Sipuleucel-T | Plicamycin | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Moderate | 1 | [
[
[
1430,
24,
397
]
],
[
[
1430,
63,
1184
],
[
1184,
24,
397
]
],
[
[
1430,
24,
384
],
[
384,
63,
397
]
],
[
[
1430,
63,
1172
],
[
1172,
... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plicamycin"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelal... |
DB00888 | DB11793 | 1,001 | 738 | [
"DDInter1133",
"DDInter1297"
] | Mechlorethamine | Niraparib | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1001,
24,
738
]
],
[
[
1001,
63,
1253
],
[
1253,
24,
738
]
],
[
[
1001,
24,
496
],
[
496,
24,
738
]
],
[
[
1001,
25,
770
],
[
770,
... | [
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palifermin"
],... | Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A ... |
DB09123 | DB13874 | 1,525 | 1,501 | [
"DDInter546",
"DDInter639"
] | Dienogest | Enasidenib | Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in... | Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible ... | Moderate | 1 | [
[
[
1525,
24,
1501
]
],
[
[
1525,
63,
1064
],
[
1064,
24,
1501
]
],
[
[
1525,
63,
1064
],
[
1064,
25,
663
],
[
663,
24,
1501
]
],
[
[
1525... | [
[
[
"Dienogest",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
]
],
[
[
"Dienogest",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cladribine"
],
[
... | Dienogest may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Dienogest may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribi... |
DB04845 | DB11718 | 309 | 927 | [
"DDInter1001",
"DDInter640"
] | Ixabepilone | Encorafenib | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
309,
24,
927
]
],
[
[
309,
63,
112
],
[
112,
23,
927
]
],
[
[
309,
63,
536
],
[
536,
24,
927
]
],
[
[
309,
25,
1259
],
[
1259,
6... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital a... |
DB01220 | DB08867 | 1,088 | 807 | [
"DDInter1593",
"DDInter1897"
] | Rifaximin | Ulipristal | Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduc... | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocor... | Moderate | 1 | [
[
[
1088,
24,
807
]
],
[
[
1088,
24,
478
],
[
478,
24,
807
]
],
[
[
1088,
24,
214
],
[
214,
63,
807
]
],
[
[
1088,
24,
1456
],
[
1456,
... | [
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ulipristal"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ulipristal
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamat... |
DB00472 | DB09291 | 758 | 741 | [
"DDInter758",
"DDInter1615"
] | Fluoxetine | Rolapitant | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
758,
24,
741
]
],
[
[
758,
25,
506
],
[
506,
24,
741
]
],
[
[
758,
40,
847
],
[
847,
24,
741
]
],
[
[
758,
24,
401
],
[
401,
24,... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
],
[
"Dext... | Fluoxetine may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Fluoxetine (Compound) resembles Atomoxetine (Compound) and Atomoxetine may cause a moderate interaction that could ... |
DB06448 | DB11837 | 171 | 1,297 | [
"DDInter1087",
"DDInter1351"
] | Lonafarnib | Osilodrostat | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Major | 2 | [
[
[
171,
25,
1297
]
],
[
[
171,
25,
1135
],
[
1135,
23,
1297
]
],
[
[
171,
63,
112
],
[
112,
23,
1297
]
],
[
[
171,
24,
466
],
[
466,
... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Lonafarnib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may ca... |
DB00991 | DB05773 | 97 | 1,047 | [
"DDInter1358",
"DDInter1848"
] | Oxaprozin | Trastuzumab emtansine | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
97,
24,
1047
]
],
[
[
97,
24,
848
],
[
848,
24,
1047
]
],
[
[
97,
24,
1613
],
[
1613,
63,
1047
]
],
[
[
97,
63,
912
],
[
912,
24... | [
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
... | Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon ... |
DB06589 | DB09080 | 1,250 | 144 | [
"DDInter1400",
"DDInter1331"
] | Pazopanib | Olodaterol | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1250,
24,
144
]
],
[
[
1250,
62,
1247
],
[
1247,
23,
144
]
],
[
[
1250,
63,
956
],
[
956,
24,
144
]
],
[
[
1250,
64,
371
],
[
371,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Pazopanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Pazopanib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and... |
DB00976 | DB08868 | 1,056 | 1,011 | [
"DDInter1758",
"DDInter737"
] | Telithromycin | Fingolimod | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1056,
25,
1011
]
],
[
[
1056,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
1056,
21,
28792
],
[
28792,
60,
1011
]
],
[
[
1056,
25,
578
],
[
... | [
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Telithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"F... | Telithromycin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Telithromycin (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fingolimod (Compound)
Telithromycin may lead to a major life threatening interaction when take... |
DB00069 | DB01004 | 367 | 563 | [
"DDInter946",
"DDInter806"
] | Interferon alfacon-1 | Ganciclovir | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
367,
24,
563
]
],
[
[
367,
24,
248
],
[
248,
40,
563
]
],
[
[
367,
24,
36
],
[
36,
63,
563
]
],
[
[
367,
25,
1101
],
[
1101,
24,... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valgan... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a modera... |
DB00604 | DB01155 | 1,425 | 872 | [
"DDInter385",
"DDInter813"
] | Cisapride | Gemifloxacin | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Major | 2 | [
[
[
1425,
25,
872
]
],
[
[
1425,
25,
956
],
[
956,
1,
872
]
],
[
[
1425,
64,
1176
],
[
1176,
1,
872
]
],
[
[
1425,
23,
112
],
[
112,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u}... | Cisapride may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin (Compound) resembles Gemifloxacin (Compound)
Cisapride may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gemifloxacin (Compound)
Cisapride may cause a ... |
DB00023 | DB01320 | 305 | 651 | [
"DDInter127",
"DDInter783"
] | Asparaginase Escherichia coli | Fosphenytoin | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
305,
24,
651
]
],
[
[
305,
24,
362
],
[
362,
1,
651
]
],
[
[
305,
24,
1479
],
[
1479,
23,
651
]
],
[
[
305,
25,
1101
],
[
1101,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with ... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetyl... |
DB00726 | DB06704 | 1,164 | 247 | [
"DDInter1876",
"DDInter951"
] | Trimipramine | Iobenguane (I-123) | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
1164,
37,
247
]
],
[
[
1164,
6,
7390
],
[
7390,
45,
247
]
],
[
[
1164,
21,
28787
],
[
28787,
60,
247
]
],
[
[
1164,
35,
820
],
[
820,
... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Trimipramine",
"{u} (Compound) binds {v} (Gene)",
"SL... | Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Trimipramine may lead to a major life threatening interaction when taken with Iobenguane
Trimipramine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Trimipramine (Compound) cau... |
DB00022 | DB00330 | 268 | 238 | [
"DDInter1408",
"DDInter689"
] | Peginterferon alfa-2b | Ethambutol | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycob... | Moderate | 1 | [
[
[
268,
24,
238
]
],
[
[
268,
63,
1057
],
[
1057,
24,
238
]
],
[
[
268,
24,
458
],
[
458,
63,
238
]
],
[
[
268,
24,
10
],
[
10,
24,... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethambutol"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etane... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Ethambutol
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00365 | DB11057 | 839 | 720 | [
"DDInter842",
"DDInter1223"
] | Grepafloxacin | Mineral oil | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
839,
24,
720
]
],
[
[
839,
25,
927
],
[
927,
63,
720
]
],
[
[
839,
25,
175
],
[
175,
24,
720
]
],
[
[
839,
64,
600
],
[
600,
24,... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"En... | Grepafloxacin may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Grepafloxacin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone may cause ... |
DB06176 | DB06212 | 1,342 | 165 | [
"DDInter1616",
"DDInter1833"
] | Romidepsin | Tolvaptan | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Moderate | 1 | [
[
[
1342,
24,
165
]
],
[
[
1342,
63,
1080
],
[
1080,
1,
165
]
],
[
[
1342,
63,
86
],
[
86,
24,
165
]
],
[
[
1342,
24,
927
],
[
927,
... | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
[
... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Tolvaptan (Compound)
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could ... |
DB12130 | DB12267 | 1,017 | 1,476 | [
"DDInter1094",
"DDInter233"
] | Lorlatinib | Brigatinib | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
1017,
25,
1476
]
],
[
[
1017,
62,
1612
],
[
1612,
23,
1476
]
],
[
[
1017,
63,
1206
],
[
1206,
23,
1476
]
],
[
[
1017,
63,
629
],
[
629... | [
[
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Lorlatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir... | Lorlatinib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Gemfibrozil and Gemfibr... |
DB00065 | DB06317 | 581 | 1,626 | [
"DDInter923",
"DDInter630"
] | Infliximab | Elotuzumab | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Major | 2 | [
[
[
581,
25,
1626
]
],
[
[
581,
25,
973
],
[
973,
24,
1626
]
],
[
[
581,
24,
1463
],
[
1463,
24,
1626
]
],
[
[
581,
24,
200
],
[
200,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elotuzumab"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} m... | Infliximab may lead to a major life threatening interaction when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause ... |
DB09046 | DB14840 | 1,094 | 861 | [
"DDInter1201",
"DDInter1601"
] | Metreleptin | Ripretinib | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
1094,
24,
861
]
],
[
[
1094,
24,
351
],
[
351,
24,
861
]
],
[
[
1094,
63,
1670
],
[
1670,
24,
861
]
],
[
[
1094,
24,
384
],
[
384,
... | [
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Elig... |
DB00448 | DB08899 | 1,215 | 129 | [
"DDInter1022",
"DDInter649"
] | Lansoprazole | Enzalutamide | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1215,
24,
129
]
],
[
[
1215,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1215,
21,
29377
],
[
29377,
60,
129
]
],
[
[
1215,
24,
851
],
[
851,
... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Lansoprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Lansoprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Lansoprazole (Compound) causes Musculoskeletal pain (Side Effect) and Musculoskeletal pain (Side Effect) is caused by Enzalutamide (Compound)
Lansoprazole may cause a moderate interaction that could exacerbate diseases whe... |
DB00569 | DB01175 | 553 | 318 | [
"DDInter775",
"DDInter672"
] | Fondaparinux | Escitalopram | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
553,
24,
318
]
],
[
[
553,
63,
1230
],
[
1230,
1,
318
]
],
[
[
553,
21,
29276
],
[
29276,
60,
318
]
],
[
[
553,
64,
834
],
[
834,
... | [
[
[
"Fondaparinux",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Fondaparinux",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
... | Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Fondaparinux (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Escitalopram (Compound)
Fondaparinux may lead to a major... |
DB00067 | DB03904 | 317 | 1,574 | [
"DDInter1921",
"DDInter1903"
] | Vasopressin | Urea | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. | Moderate | 1 | [
[
[
317,
24,
1574
]
],
[
[
317,
24,
1383
],
[
1383,
63,
1574
]
],
[
[
317,
24,
1383
],
[
1383,
24,
1399
],
[
1399,
62,
1574
]
],
[
[
317,
... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Urea"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
... | Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Urea
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate an... |
DB01211 | DB08871 | 609 | 36 | [
"DDInter393",
"DDInter666"
] | Clarithromycin | Eribulin | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
609,
24,
36
]
],
[
[
609,
63,
122
],
[
122,
23,
36
]
],
[
[
609,
62,
1247
],
[
1247,
23,
36
]
],
[
[
609,
24,
519
],
[
519,
24,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
],
... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Eribulin
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and ... |
DB00397 | DB01001 | 1,466 | 688 | [
"DDInter1458",
"DDInter1632"
] | Phenylpropanolamine | Salbutamol | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
1466,
24,
688
]
],
[
[
1466,
24,
874
],
[
874,
24,
688
]
],
[
[
1466,
63,
1636
],
[
1636,
24,
688
]
],
[
[
1466,
24,
1148
],
[
1148,
... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephri... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with P... |
DB00489 | DB00581 | 17 | 355 | [
"DDInter1704",
"DDInter1018"
] | Sotalol | Lactulose | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Moderate | 1 | [
[
[
17,
24,
355
]
],
[
[
17,
21,
29180
],
[
29180,
60,
355
]
],
[
[
17,
23,
115
],
[
115,
62,
355
]
],
[
[
17,
24,
286
],
[
286,
62,... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
]
],
[
[
"Sotalol",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal distension"
],
[
"Abdominal distension",
"{u} (Side ... | Sotalol (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Lactulose (Compound)
Sotalol may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide and Aluminum hydroxide may cause a minor interaction that can limit clinical effe... |
DB06273 | DB11627 | 980 | 1,367 | [
"DDInter1824",
"DDInter860"
] | Tocilizumab | Hepatitis B Vaccine (Recombinant) | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
980,
24,
1367
]
],
[
[
980,
63,
1560
],
[
1560,
24,
1367
]
],
[
[
980,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
980,
24,
1480
],
[
1480,
... | [
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pe... | Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Tocilizumab may lead to a major life threatening interaction when taken with Cladrib... |
DB00060 | DB00812 | 912 | 998 | [
"DDInter947",
"DDInter1451"
] | Interferon beta-1a | Phenylbutazone | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Moderate | 1 | [
[
[
912,
24,
998
]
],
[
[
912,
24,
362
],
[
362,
1,
998
]
],
[
[
912,
24,
97
],
[
97,
40,
998
]
],
[
[
912,
24,
168
],
[
168,
23,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyto... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenylbutazone (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin (Compound) resembles Phenyl... |
DB00283 | DB01181 | 701 | 1,532 | [
"DDInter395",
"DDInter906"
] | Clemastine | Ifosfamide | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
701,
24,
1532
]
],
[
[
701,
6,
8374
],
[
8374,
45,
1532
]
],
[
[
701,
21,
28956
],
[
28956,
60,
1532
]
],
[
[
701,
24,
684
],
[
684,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Clemastine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Clemastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ifosfamide (Compound)
Clemastine (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ifosfamide (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine ... |
DB00877 | DB12615 | 629 | 1,381 | [
"DDInter1678",
"DDInter1482"
] | Sirolimus | Plazomicin | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglyco... | Major | 2 | [
[
[
629,
25,
1381
]
],
[
[
629,
63,
608
],
[
608,
23,
1381
]
],
[
[
629,
25,
416
],
[
416,
24,
1381
]
],
[
[
629,
24,
1272
],
[
1272,
... | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Plazomicin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Plazomicin
Sirolimus may lead to a major life threatening interaction when taken with Kanamycin and Kanamycin may cause a modera... |
DB06791 | DB12301 | 1,446 | 907 | [
"DDInter1021",
"DDInter585"
] | Lanreotide | Doravirine | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg... | Minor | 0 | [
[
[
1446,
23,
907
]
],
[
[
1446,
24,
159
],
[
159,
62,
907
]
],
[
[
1446,
24,
951
],
[
951,
23,
907
]
],
[
[
1446,
63,
1324
],
[
1324,
... | [
[
[
"Lanreotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and P... |
DB00512 | DB00814 | 91 | 1,171 | [
"DDInter1916",
"DDInter1143"
] | Vancomycin | Meloxicam | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatm... | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Moderate | 1 | [
[
[
91,
24,
1171
]
],
[
[
91,
24,
1027
],
[
1027,
40,
1171
]
],
[
[
91,
21,
29340
],
[
29340,
60,
1171
]
],
[
[
91,
63,
1645
],
[
1645,
... | [
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
]
],
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
... | Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam (Compound) resembles Meloxicam (Compound)
Vancomycin (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Meloxicam (Compound)
Vancomycin may cau... |
DB00833 | DB01024 | 1,305 | 1,096 | [
"DDInter309",
"DDInter1252"
] | Cefaclor | Mycophenolic acid | Semisynthetic, broad-spectrum antibiotic derivative of cephalexin. | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Moderate | 1 | [
[
[
1305,
24,
1096
]
],
[
[
1305,
18,
8993
],
[
8993,
46,
1096
]
],
[
[
1305,
21,
28666
],
[
28666,
60,
1096
]
],
[
[
1305,
1,
1124
],
[
1... | [
[
[
"Cefaclor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Cefaclor",
"{u} (Compound) downregulates {v} (Gene)",
"LPAR2"
],
[
"LPAR2",
"{u} (Gene) is upregulated by {... | Cefaclor (Compound) downregulates LPAR2 (Gene) and LPAR2 (Gene) is upregulated by Mycophenolic acid (Compound)
Cefaclor (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Mycophenolic acid (Compound)
Cefaclor (Compound) resembles Cefamandole (Compound) and Cef... |
DB01181 | DB11601 | 1,532 | 1,270 | [
"DDInter906",
"DDInter1889"
] | Ifosfamide | Tuberculin purified protein derivative | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1532,
24,
1270
]
],
[
[
1532,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
1532,
63,
869
],
[
869,
24,
1270
]
],
[
[
1532,
64,
1064
],
[
1064... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Ifosfamide may cause a moderate interaction that could exacerbate diseases when ta... |
DB00414 | DB00468 | 590 | 1,424 | [
"DDInter16",
"DDInter1557"
] | Acetohexamide | Quinine | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Moderate | 1 | [
[
[
590,
24,
1424
]
],
[
[
590,
24,
1247
],
[
1247,
62,
1424
]
],
[
[
590,
63,
529
],
[
529,
23,
1424
]
],
[
[
590,
24,
1254
],
[
1254,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Quinine
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxam... |
DB00635 | DB04868 | 1,573 | 478 | [
"DDInter1515",
"DDInter1293"
] | Prednisone | Nilotinib | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1573,
24,
478
]
],
[
[
1573,
5,
11555
],
[
11555,
44,
478
]
],
[
[
1573,
6,
4973
],
[
4973,
45,
478
]
],
[
[
1573,
7,
7248
],
[
7248,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Prednisone",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease... | Prednisone (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib (Compound)
Prednisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Prednisone (Compound) upregulates RPP38 (Gene) and RPP38 (Gene) is upregulated by Nilotinib (Compound)
... |
DB00421 | DB09038 | 443 | 1,450 | [
"DDInter1707",
"DDInter636"
] | Spironolactone | Empagliflozin | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
443,
24,
1450
]
],
[
[
443,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
443,
24,
1486
],
[
1486,
24,
1450
]
],
[
[
443,
1,
312
],
[
312,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Methyl... |
DB00691 | DB14018 | 1,058 | 431 | [
"DDInter1237",
"DDInter244"
] | Moexipril | Bromotheophylline | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Bromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome. Bromotheophylline is categorized on the FDA as a ... | Moderate | 1 | [
[
[
1058,
24,
431
]
],
[
[
1058,
40,
743
],
[
743,
24,
431
]
],
[
[
1058,
63,
1061
],
[
1061,
24,
431
]
],
[
[
1058,
1,
954
],
[
954,
... | [
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromotheophylline"
]
],
[
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Lisinopril"
],
[
"Lisinopril",
"{u} may cause a mo... | Moexipril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Bromotheophylline
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction t... |
DB01035 | DB01611 | 1,401 | 1,487 | [
"DDInter1524",
"DDInter893"
] | Procainamide | Hydroxychloroquine | A derivative of procaine with less CNS action. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
1401,
25,
1487
]
],
[
[
1401,
25,
1520
],
[
1520,
25,
1487
]
],
[
[
1401,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
1401,
21,
28658
],
[
... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primaquine"
],
[
"Primaquine",
... | Procainamide may lead to a major life threatening interaction when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Procainamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Procainamide (Compound) caus... |
DB00439 | DB11989 | 289 | 1,434 | [
"DDInter341",
"DDInter183"
] | Cerivastatin | Benznidazole | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
289,
24,
1434
]
],
[
[
289,
24,
375
],
[
375,
24,
1434
]
],
[
[
289,
24,
148
],
[
148,
63,
1434
]
],
[
[
289,
63,
581
],
[
581,
... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with... |
DB06414 | DB12941 | 655 | 466 | [
"DDInter703",
"DDInter481"
] | Etravirine | Darolutamide | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
655,
24,
466
]
],
[
[
655,
24,
1446
],
[
1446,
23,
466
]
],
[
[
655,
63,
600
],
[
600,
23,
466
]
],
[
[
655,
25,
283
],
[
283,
2... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
],
[
... | Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide and Lanreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluco... |
DB00673 | DB00834 | 723 | 932 | [
"DDInter112",
"DDInter1215"
] | Aprepitant | Mifepristone | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Moderate | 1 | [
[
[
723,
24,
932
]
],
[
[
723,
6,
7524
],
[
7524,
45,
932
]
],
[
[
723,
21,
29152
],
[
29152,
60,
932
]
],
[
[
723,
62,
1101
],
[
1101,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Aprepitant",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)... | Aprepitant (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Mifepristone (Compound)
Aprepitant (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Mifepristone (Compound)
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarote... |
DB00006 | DB00465 | 942 | 886 | [
"DDInter217",
"DDInter1010"
] | Bivalirudin | Ketorolac | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Moderate | 1 | [
[
[
942,
24,
886
]
],
[
[
942,
24,
24
],
[
24,
40,
886
]
],
[
[
942,
25,
1047
],
[
1047,
63,
886
]
],
[
[
942,
25,
25
],
[
25,
24,
... | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolmetin"
],
[
... | Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin (Compound) resembles Ketorolac (Compound)
Bivalirudin may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that c... |
DB00443 | DB06674 | 251 | 908 | [
"DDInter195",
"DDInter837"
] | Betamethasone | Golimumab | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
251,
25,
908
]
],
[
[
251,
23,
1193
],
[
1193,
62,
908
]
],
[
[
251,
62,
1461
],
[
1461,
23,
908
]
],
[
[
251,
24,
336
],
[
336,
... | [
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zin... | Betamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Golimumab
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and ... |
DB00631 | DB01177 | 372 | 77 | [
"DDInter405",
"DDInter904"
] | Clofarabine | Idarubicin | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
372,
24,
77
]
],
[
[
372,
5,
11555
],
[
11555,
44,
77
]
],
[
[
372,
7,
1898
],
[
1898,
46,
77
]
],
[
[
372,
18,
1917
],
[
1917,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Clofarabine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Dise... | Clofarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Idarubicin (Compound)
Clofarabine (Compound) upregulates GADD45A (Gene) and GADD45A (Gene) is upregulated by Idarubicin (Compound)
Clofarabine (Compound) downregulates CDC25B (Gene) and CDC25B (Gene) is downregulat... |
DB02546 | DB08907 | 137 | 1,344 | [
"DDInter1947",
"DDInter280"
] | Vorinostat | Canagliflozin | Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new clas... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
137,
24,
1344
]
],
[
[
137,
24,
549
],
[
549,
1,
1344
]
],
[
[
137,
21,
29343
],
[
29343,
60,
1344
]
],
[
[
137,
63,
176
],
[
176,
... | [
[
[
"Vorinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Vorinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Vorinostat may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Vorinostat (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Canagliflozin (Compound... |
DB00618 | DB01125 | 1,572 | 279 | [
"DDInter498",
"DDInter98"
] | Demeclocycline | Anisindione | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Moderate | 1 | [
[
[
1572,
24,
279
]
],
[
[
1572,
24,
319
],
[
319,
24,
279
]
],
[
[
1572,
63,
1595
],
[
1595,
24,
279
]
],
[
[
1572,
1,
1669
],
[
1669,
... | [
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxicillin"
]... | Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Amoxicillin and Amoxicillin may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Collagenas... |
DB00398 | DB00745 | 79 | 307 | [
"DDInter1702",
"DDInter1236"
] | Sorafenib | Modafinil | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Moderate | 1 | [
[
[
79,
24,
307
]
],
[
[
79,
25,
1301
],
[
1301,
40,
307
]
],
[
[
79,
63,
362
],
[
362,
40,
307
]
],
[
[
79,
24,
1236
],
[
1236,
40,... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
],
[
"Levace... | Sorafenib may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol (Compound) resembles Modafinil (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Modafinil (Compound)
Sorafen... |
DB04951 | DB12130 | 187 | 1,017 | [
"DDInter1477",
"DDInter1094"
] | Pirfenidone | Lorlatinib | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
187,
24,
1017
]
],
[
[
187,
24,
271
],
[
271,
23,
1017
]
],
[
[
187,
63,
1387
],
[
1387,
24,
1017
]
],
[
[
187,
64,
529
],
[
529,
... | [
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
],
[
... | Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Terbinafine and Terbi... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.